Editor-in-Chief & Deputy Editor 2019-2021





Deputy Editor:




Sponsors & Partners

Acta Gastroenterologica Belgica is supported by grants from its major sponsors


Acta Gastroenterologica Belgica is supported by grants

from its major sponsors

Dr Falk Pharma







Acta Gastro-Enterologica Belgica is published in

partnership with the following national societies








Biological therapies for Inflammatory Bowel Diseases: Are we finally going to modify the disease course ?Biological therapies of inflammatory bowel disease

Biological therapies for ulcerative colitis

Price: €10,00

(Acta gastroenterol. belg., 2001, 64, 205-209)

April-June Volume 64, fasc. 2

Biological therapies for ulcerative colitis

B.E. Sands. Gastrointestinal Unit and Center for the Study of IBD, Massachusetts General Hospital, Boston, U.S.A.

Biological therapies are being increasingly investigated for the treatment of inflammatory bowel disease. However, a great deal more study has been devoted to studies of Crohn's disease rather than ulcerative colitis. Ulcerative colitis, like Crohn's disease, represents an area of high clinical need, particularly for those patients who have disease inadequately responsive to corticosteroids and 5aminosalicylates. The distinct anatomic distribution of inflammation in ulcerative colitis represents an important model for study, with the entire involved mucosa entirely accessible to endoscopy. In addition, there is an opportunity for local delivery of biologic agents in left-sided disease. Distinct pathogenetic factors in ulcerative colitis raise the possibility of therapies quite different from those used in Crohn's disease. This work describes the current state of knowledge regarding biological therapy in ulcerative colitis. The role of probiotic therapy, and studies of cytokine-directed therapies, therapies targeting adhesion and recruitment, and restitution and repair are described.